How long does it take to see the therapeutic effect of Ustekinumab injection?

Ustekinumab is a monoclonal antibody targeting interleukin -12 and interleukin -23. It is widely used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. In clinical practice, most patients begin to observe signs of symptom improvement within 2 to 4 weeks after receiving the first subcutaneous injection, such as reduced skin itching, reduced erythema area, or decreased frequency of diarrhea. Some patients take longer, and the effect is usually more significant after receiving 2 doses or 12 weeks.

The onset time of ustekinumab is slightly different for different diseases. For example, among patients with psoriasis, clinical studies have shown that approximately 70% of patients can see PASI by 4 weeks. >Improvement of scores (psoriasis skin lesion assessment); for chronic inflammatory diseases of the intestines such as Crohn's disease, it may take 8 to 12 weeks to achieve significant effects, because the intestinal mucosal repair process is slow. This shows that the speed of onset of action is not only related to the drug itself, but also affected by the nature of the disease and individual differences.

The patient's weight, disease severity, and whether other treatments (such as glucocorticoids or immunomodulators) are combined will affect the onset time of ustekinumab. For example, patients who are heavier or whose condition has not been controlled for a long time may take longer to see significant improvement. In addition, if the patient has good medication compliance during the initial treatment period and receives injections on time, the efficacy is usually more ideal. Doctors will also evaluate whether to adjust the dosage regimen or use it in combination with other drugs based on the patient's specific response.

Since ustekinumab is not a quick-acting drug, patients need to be patient in the early stages of treatment and follow the doctor's arrangements for periodic evaluations. Even if the effect is not significant in the first 4 weeks, it does not mean that the drug has failed. Instead, it is necessary to continue to observe the effect trend as planned. Clinical experience shows that with continuous use for more than 12 weeks, the vast majority of patients can achieve satisfactory results. Therefore, you should not blindly change medications or interrupt medication during treatment. Instead, you should communicate closely with your doctor to jointly develop a long-term management plan suitable for your condition.

Reference materials:https://www.drugs.com/donanemab.html